raloxifene hydrochloride has been researched along with dronabinol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Howlett, AC; Ruh, MF; Taylor, JA; Welshons, WV | 1 |
| Kumar, P; Song, ZH | 1 |
2 other study(ies) available for raloxifene hydrochloride and dronabinol
| Article | Year |
|---|---|
Failure of cannabinoid compounds to stimulate estrogen receptors.
Topics: Breast Neoplasms; Cannabinoids; Cell Division; Dronabinol; Estrogens; Humans; Phenanthridines; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Transcriptional Activation; Tumor Cells, Cultured | 1997 |
Identification of raloxifene as a novel CB2 inverse agonist.
Topics: Benzoxazines; Binding, Competitive; Bone Density Conservation Agents; Colforsin; Cyclic AMP; Cyclohexanols; Dose-Response Relationship, Drug; Dronabinol; Drug Approval; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Morpholines; Naphthalenes; Raloxifene Hydrochloride; Receptor, Cannabinoid, CB2; Transfection; Tritium; United States; United States Food and Drug Administration | 2013 |